Loading
Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Afmn Biomedicine · September 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage exploratory study demonstrating that halogenated boroxine alters specific hematological parameters in rats in a route-dependent manner and inhibits creatine kinase in vitro through a mechanism that shifts from competitive to non-competitive with pre-incubation. The work is mechanistic and preclinical; no clinical efficacy, safety threshold, or human applicability has been established.
Experimental study: in vivo rat model with route-of-administration comparison and in vitro enzyme kinetics. Laboratory rats; route of administration (IP vs. oral) was varied. In vitro: creatine kinase enzyme.. Intervention: Halogenated boroxine administered intraperitoneally or orally. Compared with: Control animals (unspecified); in vitro creatine kinase activity with and without pre-incubation.
IP administration significantly increased neutrophils, MCH, and MCHC, while decreasing hematocrit Oral administration significantly decreased lymphocytes and increased basophils; other hematological parameters remained unchanged Halogenated boroxine exhibited competitive inhibition of creatine kinase without pre-incubation
No dosage, duration of treatment, or toxicity threshold specified
The source did not state who this applies to in practice.
Early mechanistic study combining in vivo rat toxicology with in vitro enzyme kinetics, lacking clinical endpoints, controls for confounding, or quantified effect sizes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Halogenated boroxine is an important enzyme inhibitor with potential applications in cancer therapy. This study aimed to evaluate its effects on hematological parameters in rats in vivo and creatine kinase activity in vitro. Halogenated boroxine, administered either intraperitoneally (IP) or orally, induced route-dependent changes in hematological parameters compared with controls. IP administration significantly increased neutrophils, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC), while decreasing hematocrit (HCT). In contrast, oral administration significantly decreased lymphocytes and increased basophils, while other hematological parameters remained unchanged. These effects were more pronounced following IP administration. In vitro, halogenated boroxine exhibited competitive inhibition of creatine kinase without pre-incubation, whereas after a 30-minute pre-incubation, the inhibition pattern indicated a non-competitive mechanism. Further analysis showed a time-dependent shift in creatine kinase inhibition mechanism following pre-incubation, characterized by a decrease in maximum reaction velocity (Vmax), while the Michaelis constant (Km) remained unaltered. These findings show that halogenated boroxine modulates specific hematological parameters and inhibits creatine kinase activity, with effects depending on the route of administration and experimental conditions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.